Shitara K, Lordick F, Bang YJ, Enzinger P, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 tr Lancet 2023;401:1655-1668.
PMID: 37068504